# INVI MindHealth

**Location:** Denver, Colorado

**Focus:** Real-time biomarker platform for neuromodulation and psychedelic therapies

**Stage:** Selected for ARPA-H EVIDENT initiative

## Technology Platform

Real-time biomarker monitoring system designed to:
- Track physiological responses during neuromodulation treatments
- Monitor psychedelic therapy sessions
- Generate FDA-ready clinical endpoint data

## Strategic Position

INVI MindHealth represents the biomarker infrastructure layer for behavioral health interventions—addressing the measurement gap that has historically limited psychedelic and neuromodulation research. Real-time monitoring enables:
1. Objective outcome measurement beyond self-reported scales
2. Safety monitoring during treatment sessions
3. Dose-response optimization
4. Mechanistic understanding of therapeutic effects

## Timeline

- **2026-04-24** — Selected as ARPA-H EVIDENT research team for real-time biomarker platform development

## Analysis

The biomarker platform addresses a critical gap in psychedelic research: functional unblinding (patients and clinicians knowing who received active drug) invalidates self-reported outcomes in highly psychoactive compounds. Objective biomarkers could provide unblinding-resistant endpoints, strengthening regulatory submissions.

ARPA-H's selection of a biomarker platform company (rather than only drug developers) signals recognition that measurement infrastructure is a binding constraint on FDA approval pathways for behavioral health interventions.